Durvalumab after Chemoradiotherapy in Stage III Non-small-cell Lung Cancer

  • Phaszon Akaranithithanayot
Keywords: durvalumab, lung cancer, non-small cell lung cancer, anti PD-L1


Hepatocellular carcinoma (HCC) is a major global health problem and the most frequent primary liver tumor. Although there are widespread applications of cancer-screening systems to detect early-stage HCC, a significant proportion of patients are still diagnosed with non-resectable HCC. In Thailand, according to the Thai Association for the Study of the Liver, which is an improved version of Barcelona Clinic Liver Cancer (BCLC) staging, the advanced stage characterizes patients with cancer-related symptoms, macrovascular invasion (either segmental or main portal vein) or extrahepatic spread (lymph node involvement),or metastases. Untreated advanced-stage HCC had a poor prognosis, with a survival time of 6-8 months; survival at 1 year was 25%. There are currently many treatments for  advanced HCC, one of which is systemic therapy. Sorafenib was the first molecular target agent with supportive evidence of survival benefits; it has now become the first-line treatment for patients with advanced HCC. In the past few years, more agents have been approved by the USFDA for patients with advanced HCC. This article reviews the role of the currently approved systemic therapy for advanced HCC according to the National Comprehensive Cancer Network (NCCN) guidelines.


Download data is not yet available.


Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide

for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

Suwanrungruang K, Pongnikorn D, Buasom R. Cancer Incidence in Thailand. In: Imsamran W, Pattatang A, Supaattagorn P, Chiawiriyabunya I,

Namthaisong K, Wongsena M, et al., editor. Cancer in Thailand Vol. IX, 2013-2015. Bangkok: New Thammada Press; 2018. P.10-11.

Allemani C, Matsuda T, Carlo VD, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-2014 (CONCORD-3)

: analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in

countries. Lancet 2018;391:1023-51.

Bade BC, Cruz CSD. Lung Cancer 2020 Epidemiology, Etiology, and Prevention. Clin Chest Med 2020;41:1-24.

Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 world health organization classification of lung

tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243-60.

Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell

lung cancer. World J Clin Oncol 2017;8:1–20.

สุพัตรา รักเอียด, ศุกล ภักดีนิติ, วิษณุ ปานจันทร์, อาคม ชัยวีระวัฒนะ, วีรวุฒิ อิ่มสำราญ, บรรณาธิการ. แนวทางการตรวจรักษาและวินิจฉัยโรคมะเร็งปอด (ปรับปรุงครั้งที่ 2).

กรุงเทพฯ: บริษัท โฆสิตการพิมพ์ จำกัด; 2558.

Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant

versus sequential radiochemotherapyin locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.

Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, et al. Immune checkpoint inhibitors for lung cancer

treatment: A review. J Clin Med 2020;9 :1362.

Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al. Identification and characterization of MEDI4736,

an antagonistic anti-PD-L1monoclonal antibody. Cancer ImmunolRes 2015;3:1052-62.

Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1

antibodies atezolizumab and durvalumab. Sci Rep 2017;7:5532.

Imfinzi® (durvalumab) [package insert]. England, AstraZeneca UK Limited.; 2018. Available at:https://www.accessdata.fda.gov/

drugsatfda_docs/label/2018/761069s002lbl.pdf. Accessed April 22, 2020.

Antonia SJ, Villegas A, Daniel D, Vicente D, Hui R, et at. Durvalumab after chemoradiotherapy

in stage III non–small-cell lung cancer. N Engl J Med 2017;377:1919-29.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et at. Overall survival with durvalumab after chemoradiotherapy in stage III

NSCLC. N Engl J Med 2018. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa 1809697. Accessed April 22, 2020.

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Three-year overall survival with durvalumab after chemoradio-

therapy in stage III NSCLC-update from PACIFIC. J Thorac Oncol 2020;15:288-93.

Review Articles